GLP1R and metastatic malignant neoplasm: This comprehensive NMA reveals a potentially important breakthrough in metastatic cancer prevention, demonstrating that the long half-life GLP-1 receptor agonist, the efpeglenatide, significantly reduces the risk of metastatic cancer (OR = 0.26, 95%CIs = 0.09 to 0.70) with an acceptable NNT value (188.4).